open access

Vol 21, No 1 (2018)
Original articles
Published online: 2017-09-21
Submitted: 2017-05-15
Accepted: 2017-08-09
Get Citation

The assessment of testosterone and radioisotopic index of bone metabolism and bone mineral density in men with testosterone deficiency after one year of testosterone therapy

Wieslaw Tryniszewski, Grzegorz Kamiński, Zbigniew Maziarz, Michal Nowak, Mariusz Gadzicki, Maciej Radek
DOI: 10.5603/NMR.a2018.0002
·
Pubmed: 29319133
·
Nucl. Med. Rev 2018;21(1):14-19.

open access

Vol 21, No 1 (2018)
Original articles
Published online: 2017-09-21
Submitted: 2017-05-15
Accepted: 2017-08-09

Abstract

Background: Testosterone deficiency in men is characterized by typical symptoms of hypogonadism and negative influence on the preservation of bone mass. In this study, we analysed the relationship between testosterone concentration and bone metabolism. Moreover, we assessed the impact of one-year compensation of testosterone deficiency in elderly men on bone metabolism and bone mineral density. Radioisotopic methods of bone metabolism assessment provide new research opportunities. Materials and methods: Men with total testosterone concentration (TT) ≤ 3 ng/ml were included into this study. Patients with disorders or injuries of bone system, elevated prostate-specific antigen (PSA), enlarged prostate, disorders of thyroid and liver, diabetes mellitus or a history of chemotherapy as well as those treated for a long time with antibiotics were excluded from this study. The results of 50 men aged 57.52 ± 6.71 years obtained before the treatment (I test) and after one year of oral testosterone supplementation (test II) were analysed in this study. The following examinations and analyses were performed: interview and physical examination, orthopaedic, neurological and urological consultations, blood biochemistry, determination of hormones levels, assessment of Testosterone Deficiency Syndrome (TDS), densitometric and radioisotope assessment of bone metabolism. Moreover, radioisotopic index of bone metabolism was calculated. Testosterone therapy with oral preparation Undestor Testo Caps (Organon) containing 40 mg of testosterone lasted for 12 months. Statistical analysis was performed using Statistica 12 and Excel 2010 programs. Correlations between results before and after treatment were analysed. Results: After 12 months of treatment, testosterone concentration increased by mean 78% and the level of luteinizing hormone (LH) decreased by 62%. TDS index increased from 0.53 ± 0.21 (in test I) to 1.91 ± 0.60 (in test II). After the therapy this index was significantly higher in all men (p < 0.0001). Moreover, BMD was also improved following therapy, however, the difference between test I and II was statistically insignificant. The greatest change was found in case of IBM (Index of Bone Metabolism). We observed a positive correlation between IBM and BMD before treatment (r = 0.7991), however, its strength decreased after one-year therapy (r = 0.6757). Conclusions: In our opinion, IBM is more sensitive than other methods of the assessment of changes occurring in bone system under the influence of testosterone therapy. The observed changes in IBM were proportional to changes in testosterone concentration. Testosterone level, TDS and radioisotopic assessment of bone metabolism may be used as prognostic and therapeutic factors of osteoporosis and bone fractures in elderly men.  

Abstract

Background: Testosterone deficiency in men is characterized by typical symptoms of hypogonadism and negative influence on the preservation of bone mass. In this study, we analysed the relationship between testosterone concentration and bone metabolism. Moreover, we assessed the impact of one-year compensation of testosterone deficiency in elderly men on bone metabolism and bone mineral density. Radioisotopic methods of bone metabolism assessment provide new research opportunities. Materials and methods: Men with total testosterone concentration (TT) ≤ 3 ng/ml were included into this study. Patients with disorders or injuries of bone system, elevated prostate-specific antigen (PSA), enlarged prostate, disorders of thyroid and liver, diabetes mellitus or a history of chemotherapy as well as those treated for a long time with antibiotics were excluded from this study. The results of 50 men aged 57.52 ± 6.71 years obtained before the treatment (I test) and after one year of oral testosterone supplementation (test II) were analysed in this study. The following examinations and analyses were performed: interview and physical examination, orthopaedic, neurological and urological consultations, blood biochemistry, determination of hormones levels, assessment of Testosterone Deficiency Syndrome (TDS), densitometric and radioisotope assessment of bone metabolism. Moreover, radioisotopic index of bone metabolism was calculated. Testosterone therapy with oral preparation Undestor Testo Caps (Organon) containing 40 mg of testosterone lasted for 12 months. Statistical analysis was performed using Statistica 12 and Excel 2010 programs. Correlations between results before and after treatment were analysed. Results: After 12 months of treatment, testosterone concentration increased by mean 78% and the level of luteinizing hormone (LH) decreased by 62%. TDS index increased from 0.53 ± 0.21 (in test I) to 1.91 ± 0.60 (in test II). After the therapy this index was significantly higher in all men (p < 0.0001). Moreover, BMD was also improved following therapy, however, the difference between test I and II was statistically insignificant. The greatest change was found in case of IBM (Index of Bone Metabolism). We observed a positive correlation between IBM and BMD before treatment (r = 0.7991), however, its strength decreased after one-year therapy (r = 0.6757). Conclusions: In our opinion, IBM is more sensitive than other methods of the assessment of changes occurring in bone system under the influence of testosterone therapy. The observed changes in IBM were proportional to changes in testosterone concentration. Testosterone level, TDS and radioisotopic assessment of bone metabolism may be used as prognostic and therapeutic factors of osteoporosis and bone fractures in elderly men.  
Get Citation

Keywords

testosterone, bone metabolism, densitometry

About this article
Title

The assessment of testosterone and radioisotopic index of bone metabolism and bone mineral density in men with testosterone deficiency after one year of testosterone therapy

Journal

Nuclear Medicine Review

Issue

Vol 21, No 1 (2018)

Pages

14-19

Published online

2017-09-21

DOI

10.5603/NMR.a2018.0002

Pubmed

29319133

Bibliographic record

Nucl. Med. Rev 2018;21(1):14-19.

Keywords

testosterone
bone metabolism
densitometry

Authors

Wieslaw Tryniszewski
Grzegorz Kamiński
Zbigniew Maziarz
Michal Nowak
Mariusz Gadzicki
Maciej Radek

References (19)
  1. Marek M. Leczenie testosteronem. MedPharma Polska 2013.
  2. Zgliczyński S, Rabijewski M, Wiktorowicz-Dudek A. Wskaźnik andropauzy w rozpoznawaniu i leczeniu ujawniającego się z wiekiem hipogonadyzmu. Endokrynologia Polska. 2003; 2(54): 148–154.
  3. Torremadé-Barreda J, Rodríguez-Tolrà J, Román-Romera I, et al. [Testosterone-deficiency as a risk factor for hip fracture in eldery men]. Actas Urol Esp. 2013; 37(3): 142–146.
  4. Kang HY, Cho CL, Huang KL, et al. Nongenomic androgen activation of phosphatidylinositol 3-kinase/Akt signaling pathway in MC3T3-E1 osteoblasts. J Bone Miner Res. 2004; 19(7): 1181–1190.
  5. Balkan W, Burnstein KL, Schiller PC, et al. Androgen-induced mineralization by MC3T3-E1 osteoblastic cells reveals a critical window of hormone responsiveness. Biochem Biophys Res Commun. 2005; 328(3): 783–789.
  6. Wiren KM, Chapman Evans A, Zhang XW. Osteoblast differentiation influences androgen and estrogen receptor-alpha and -beta expression. J Endocrinol. 2002; 175(3): 683–694.
  7. Chen Q, Kaji H, Sugimoto T, et al. Testosterone inhibits osteoclast formation stimulated by parathyroid hormone through androgen receptor. FEBS Lett. 2001; 491(1-2): 91–93.
  8. Tryniszewski W, Maziarz Z, Kulińska M. Przydatność scyntygraficznej oceny jakości i metabolizmu tkanki kostnej u osób z osteoporozą. Endokrynol Pol. 2005; 56(4): 483.
  9. Tryniszewski W, Gadzicki M, Maziarz Z. Wykorzystanie własnego programu i metody scyntygrafii dynamicznej i statycznej kości do matematycznej analizy metabolizmu kostnego i porównanie z gęstością mineralną kości w aspekcie ich przydatności klinicznej. Kwartalnik Ortopedyczny. 2006; 4: 296.
  10. Tryniszewski W, Gadzicki M, Rysz J, et al. The behaviour of bone mineral density and bone metabolism index in young and menopausal women with the consideration of body mass index. Med Sci Monit. 2010; 16(7): 342–347.
  11. Tryniszewski W, Sobczuk A, Górska-Chrząstek M. The assessment of indicator of bone metabolism (IBM) and designation of its normal values range in healthy women and men. Przegląd Menopauzalny. 2011; 1(53): 50–57.
  12. Wang C, Swerdloff RS, Iranmanesh A, et al. Testosterone Gel Study Group. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000; 85(8): 2839–2853.
  13. Chin KY, Ima-Nirwana S. Sex Steroids and Bone Health Status in Men. International Journal of Endocrinology. 2012; 2012: 1–7.
  14. Kung AWC. Androgen and bone mass in men. Asian J Androl. 2003; 5(2): 148–154.
  15. Travison TG, Araujo AB, Kupelian V, et al. The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab. 2007; 92(2): 549–555.
  16. Aversa A, Bruzziches R, Francomano D, et al. Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study. Aging Male. 2012; 15(2): 96–102.
  17. Kok-Yong C, Soelaiman IN. Sex Steroids and Bone Health Status in Men. International Journal of Endocrinology. 2012; 2012: 1–7.
  18. Ramin S, Seyed RZ, Masrour G, et al. Age-related changes in skull uptake on bone scintigraphy: a quantitative study. Nuc Med Rev. 2008; 11(2): 67–69.
  19. Szulc P, Uusi-Rasi K, Claustrat B, et al. Role of sex steroids in the regulation of bone morphology in men. The MINOS study. Osteoporos Int. 2004; 15(11): 909–917.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl